论文部分内容阅读
目的探讨盐酸氨溴索辅助治疗加重期慢性阻塞性肺疾病(COPD)的临床疗效。方法选择2011年7月—2015年9月泉州市第一医院接治的加重期COPD患者94例,随机分为对照组与治疗组,各47例。对照组给予常规治疗,治疗组在对照组基础上给予盐酸氨溴索辅助治疗,比较两组患者的临床疗效、治疗前后肺功能〔第1秒末用力呼气容积(FEV_1)、用力肺活量(FVC)、FEV_1/FVC〕、症状消失时间及不良反应发生情况。结果治疗组总有效率高于对照组(P<0.05)。治疗前两组患者FEV_1、FVC以及FEV_1/FVC比较,差异无统计学意义(P>0.05);治疗后治疗组FEV_1、FVC以及FEV_1/FVC高于对照组(P<0.05)。治疗后治疗组肺部哮鸣音消失、咳嗽、咳痰好转、喘憋缓解、呼吸困难缓解、体温恢复正常时间均短于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论盐酸氨溴索治疗加重期COPD临床疗效确切,可有效改善患者肺功能,缓解症状,提高患者生活质量,不良反应少。
Objective To investigate the clinical efficacy of ambroxol hydrochloride in the treatment of exacerbation chronic obstructive pulmonary disease (COPD). Methods From July 2011 to September 2015, 94 patients with exacerbated COPD admitted to the First Hospital of Quanzhou were randomly divided into control group and treatment group, with 47 cases in each group. The control group was given routine treatment. The treatment group was given ambroxol hydrochloride on the basis of the control group, and the clinical efficacy was compared between the two groups. Before and after treatment, lung function (forced expiratory volume at 1 second (FEV 1), forced vital capacity ), FEV_1 / FVC〕, symptoms disappear time and the occurrence of adverse reactions. Results The total effective rate of the treatment group was higher than that of the control group (P <0.05). There were no significant differences in FEV 1, FVC and FEV 1 / FVC between the two groups before treatment (P> 0.05). After treatment, the FEV 1, FVC and FEV 1 / FVC in the treatment group were higher than those in the control group (P <0.05). After treatment, lung wheeze disappeared, cough and sputum improved, wheezing relieved, dyspnea relief and temperature returned to normal in both groups were shorter than those in control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Ambroxol Hydrochloride for the treatment of exacerbated COPD has definite clinical curative effect, which can effectively improve lung function, relieve symptoms and improve quality of life of patients with less adverse reactions.